HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
HTG Molecular Diagnostics will present a fireside chat at Cantor Fitzgerald’s Virtual Global Healthcare Conference from September 27-30, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics will present a fireside chat at Cantor Fitzgerald’s Virtual Global Healthcare Conference from September 27-30, 2021. The chat is scheduled for September 30 at 2:00 PM Eastern / 11:00 AM Pacific. Management will also hold 1x1 meetings during the conference. The company focuses on advancing precision medicine through transcriptome-wide profiling for various disease areas. Interested participants can access the webcast here.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was +1.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Sept. 21, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will present in a fireside chat in Cantor Fitzgerald’s Virtual Global Healthcare Conference, being held September 27th – 30th, 2021.
Details for the fireside chat are below:
| Date: | Thursday, September 30, 2021 |
| Time: | 2:00 PM Eastern / 11:00 AM Pacific |
| Webcast: | https://wsw.com/webcast/cantor12/htgm/2086560 |
Management will also be available for 1x1 meetings. If you would like to request a meeting, please email corporateaccess@cantor.com
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptnome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Contact:
Ashley Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.